Arcturus Therapeutics Holdings (ARCT) Operating Expenses (2018 - 2026)

Arcturus Therapeutics Holdings has reported Operating Expenses for 9 years, with the latest figure at -$2.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 28.47% year-over-year to -$2.0 million; the trailing twelve-month figure through Mar 2026 stood at -$101.0 million (up 37.18% YoY), and the FY2025 full-year result was -$10.5 million, up 28.86% from the prior year.
• Operating Expenses for Q1 2026 stood at -$2.0 million, up from -$130.3 million in the prior quarter.
• The five-year high for Operating Expenses was $68.4 million in Q1 2024, with the low at -$206.5 million in Q4 2024.
• Historically, Operating Expenses has averaged $14.4 million across 5 years, with a median of $49.1 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Expenses tumbled 520.43% — and 2025, when it jumped 37.7%.
• Arcturus Therapeutics Holdings' Operating Expenses stood at $38.8 million in 2022, then advanced by 26.48% to $49.1 million in 2023, then plunged by 520.43% to -$206.5 million in 2024, then jumped by 36.93% to -$130.3 million in 2025, then surged by 98.49% to -$2.0 million in 2026.
• The last three Operating Expenses figures came in at -$2.0 million (Q1 2026), -$130.3 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.